Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival
胰腺腺癌的临床基因组学分析表明,KRAS突变剂量可作为总生存期的预后指标
期刊:Nature Medicine
影响因子:50
doi:10.1038/s41591-024-03362-3
Varghese, Anna M; Perry, Maria A; Chou, Joanne F; Nandakumar, Subhiksha; Muldoon, Daniel; Erakky, Amanda; Zucker, Amanda; Fong, Christopher; Mehine, Miika; Nguyen, Bastien; Basturk, Olca; Balogun, Fiyinfolu; Kelsen, David P; Brannon, A Rose; Mandelker, Diana; Vakiani, Efsevia; Park, Wungki; Yu, Kenneth H; Stadler, Zsofia K; Schattner, Mark A; Jarnagin, William R; Wei, Alice C; Chakravarty, Debyani; Capanu, Marinela; Schultz, Nikolaus; Berger, Michael F; Iacobuzio-Donahue, Christine A; Bandlamudi, Chaitanya; O'Reilly, Eileen M